Mergenthaler, Philipp http://orcid.org/0000-0002-9753-6711
Stetefeld, Henning R.
Dohmen, Christian
Kohler, Siegfried
Schönenberger, Silvia
Bösel, Julian
Gerner, Stefan T.
Huttner, Hagen B.
Schneider, Hauke
Reichmann, Heinz
Fuhrer, Hannah
Berger, Benjamin
Zinke, Jan
Alberty, Anke
Kleiter, Ingo
Schneider-Gold, Christiane
Roth, Christian
Dunkel, Juliane
Steinbrecher, Andreas
Thieme, Andrea
Lee, De-Hyung
Linker, Ralf A.
Angstwurm, Klemens
Meisel, Andreas http://orcid.org/0000-0001-7233-5342
Neumann, Bernhard http://orcid.org/0000-0001-8254-8616
,
Funding for this research was provided by:
Universitätsklinikum Regensburg
Article History
Received: 19 November 2021
Revised: 7 February 2022
Accepted: 10 February 2022
First Online: 7 April 2022
Declarations
:
: Philipp Mergenthaler is on the Advisory Board of HealthNextGen Inc. and has equity interest in the company, within the scope of the present work, but not directly related; Henning R. Stetefeld reports no disclosures; Christian Dohmen reports no disclosures; Siegfried Kohler reports no disclosures; Silvia Schönenberger reports no disclosures; Julian Bösel reports personal fees from Medtronic, personal fees from Zoll, personal fees from Boehringer Ingelheim, personal fees from Sedana Medical, personal fees from PCORI, outside the submitted work. Stefan T. Gerner reports no disclosures; Hagen B. Huttner reports personal fees from Daiichi Sanyko, grants and personal fees from Novartis, grants and personal fees from UCB Pharma, grants and personal fees from Portola Pharmaceuticals, personal fees from Bayer AG, personal fees from Boehringer Ingelheim, personal fees from Prediction BioSciences, outside the submitted work; Hauke Schneider reports no disclosures; Heinz Reichmann reports no disclosures; Hannah Fuhrer reports no disclosures; Benjamin Berger received travel grants and/or training expenses from Bayer Vital GmbH, Ipsen Pharma GmbH, Novartis, Biogen GmbH, Merck Serono GmbH, and Genzyme, as well as lecture fees from Ipsen Pharma GmbH, Alexion Pharma Germany GmbH, Merck Serono GmbH, Sanofi Genzyme, and Roche Pharma AG outside the submitted work; Jan Zinke reports no disclosures; Anke Alberty reports no disclosures; Ingo Kleiter reports personal fees from Biogen, personal fees from Novartis, personal fees from Merck, personal fees from Sanofi Genzyme, personal fees from Roche, personal fees from Mylan, personal fees from Alexion, personal fees from Celgene, grants and personal fees from Chugai, personal fees from IQVIA, outside the submitted work; Christiane Schneider-Gold has received consulting and/or speaker's honoraria from Alexion Pharmaceuticals, Amicus Therapeutics, Bayer Schering, CSL Behring, Grünenthal, Hormosan, Lupin Pharmaceuticals, and TEVA outside the submitted work; Christian Roth reports no disclosures; Juliane Dunkel reports no disclosures; Andreas Steinbrecher reports no disclosures; Andrea Thieme reports no disclosures; De-Hyung Lee reports no disclosures; Ralf Linker reports no disclosures; Klemens Angstwurm reports no disclosures; Andreas Meisel reports personal fees from Hormosan, personal fees from Grifols, grants and personal fees from Alexion, personal fees from Argnx, personal fees from Novartis, personal fees from UCB, grants from Octapharma, outside the submitted work. Bernhard Neumann reports no disclosures. The authors declare no financial or other conflicts of interest related to the manuscript. Statistical analysis was conducted by Dr. Bernhard Neumann, University Medical Center Regensburg/Donau-Isar-Klinikum Deggendorf.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local ethic committees and institutional review boards of the participating centers approved the study based on the central vote of the ethics committee at University of Regensburg (No. 15–101-0259). Due to the retrospective character of the study, patient`s consent was not necessary according to the decisions of the ethic committees and institutional review boards.